These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21900558)

  • 1. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.
    Alexandru A; Jagla W; Graubner S; Becker A; Bäuscher C; Kohlmann S; Sedlmeier R; Raber KA; Cynis H; Rönicke R; Reymann KG; Petrasch-Parwez E; Hartlage-Rübsamen M; Waniek A; Rossner S; Schilling S; Osmand AP; Demuth HU; von Hörsten S
    J Neurosci; 2011 Sep; 31(36):12790-801. PubMed ID: 21900558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration.
    Becker A; Kohlmann S; Alexandru A; Jagla W; Canneva F; Bäuscher C; Cynis H; Sedlmeier R; Graubner S; Schilling S; Demuth HU; von Hörsten S
    BMC Neurosci; 2013 Oct; 14():108. PubMed ID: 24083638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.
    Frost JL; Liu B; Kleinschmidt M; Schilling S; Demuth HU; Lemere CA
    Neurodegener Dis; 2012; 10(1-4):265-70. PubMed ID: 22343072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
    Wirths O; Bethge T; Marcello A; Harmeier A; Jawhar S; Lucassen PJ; Multhaup G; Brody DL; Esparza T; Ingelsson M; Kalimo H; Lannfelt L; Bayer TA
    J Neural Transm (Vienna); 2010 Jan; 117(1):85-96. PubMed ID: 19823761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
    Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
    Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.
    Wittnam JL; Portelius E; Zetterberg H; Gustavsson MK; Schilling S; Koch B; Demuth HU; Blennow K; Wirths O; Bayer TA
    J Biol Chem; 2012 Mar; 287(11):8154-62. PubMed ID: 22267726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease.
    Moro ML; Phillips AS; Gaimster K; Paul C; Mudher A; Nicoll JAR; Boche D
    Acta Neuropathol Commun; 2018 Jan; 6(1):3. PubMed ID: 29298722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
    Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
    Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
    Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.
    Jawhar S; Wirths O; Schilling S; Graubner S; Demuth HU; Bayer TA
    J Biol Chem; 2011 Feb; 286(6):4454-60. PubMed ID: 21148560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.
    Wirths O; Breyhan H; Cynis H; Schilling S; Demuth HU; Bayer TA
    Acta Neuropathol; 2009 Oct; 118(4):487-96. PubMed ID: 19547991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminopeptidase A contributes to biochemical, anatomical and cognitive defects in Alzheimer's disease (AD) mouse model and is increased at early stage in sporadic AD brain.
    Valverde A; Dunys J; Lorivel T; Debayle D; Gay AS; Lacas-Gervais S; Roques BP; Chami M; Checler F
    Acta Neuropathol; 2021 Jun; 141(6):823-839. PubMed ID: 33881611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease.
    Jawhar S; Wirths O; Bayer TA
    J Biol Chem; 2011 Nov; 286(45):38825-32. PubMed ID: 21965666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
    Cynis H; Scheel E; Saido TC; Schilling S; Demuth HU
    Biochemistry; 2008 Jul; 47(28):7405-13. PubMed ID: 18570439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.
    Dunkelmann T; Schemmert S; Honold D; Teichmann K; Butzküven E; Demuth HU; Shah NJ; Langen KJ; Kutzsche J; Willbold D; Willuweit A
    J Alzheimers Dis; 2018; 63(1):115-130. PubMed ID: 29578479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-β3-42 (pE3-Aβ).
    Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Wegiel J; Wisniewski T; Miller DL
    J Alzheimers Dis; 2018; 62(4):1635-1649. PubMed ID: 29504532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.
    Mandler M; Rockenstein E; Ubhi K; Hansen L; Adame A; Michael S; Galasko D; Santic R; Mattner F; Masliah E
    J Alzheimers Dis; 2012; 28(4):783-94. PubMed ID: 22064070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.
    Hartlage-Rübsamen M; Waniek A; Meissner J; Morawski M; Schilling S; Jäger C; Kleinschmidt M; Cynis H; Kehlen A; Arendt T; Demuth HU; Rossner S
    Acta Neuropathol; 2015 Apr; 129(4):565-83. PubMed ID: 25666182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.